# Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer

> **NCT00081315** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 130 (—)

## Conditions studied

- Esophagitis
- Pneumonitis
- Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Amifostine

## Key facts

- **NCT ID:** NCT00081315
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** 130 (—)
- **Last updated:** 2007-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00081315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00081315, "Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00081315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*